Letter to the Editor | Published:

Vedolizumab as a Novel Treatment for Refractory Collagenous Colitis: A Case Report

The American Journal of Gastroenterology volume 113, pages 632633 (2018) | Download Citation

Subjects

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    , , et al. Incidence, prevalence, and temporal trends of microscopic colitis: a systematic review and meta-analysis. Am J Gastroenterol 2015;110:265–276.

  2. 2.

    . Diagnosis and management of microscopic colitis. Am J Gastroenterol 2017;112:78–85.

  3. 3.

    , , et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med 2013;369:699–710.

  4. 4.

    , , . Vedolizumab as induction and maintenance therapy for Crohn's disease. N Engl J Med 2013;369:711–721.

  5. 5.

    , , et al. Microscopic colitis: what do we know about pathogenesis? Inflamm Bowel Dis 2016;22:450–458.

Download references

Author information

Affiliations

  1. Division of Gastroenterology, Crohn’s and Colitis Center, Massachusetts General Hospital, Boston, Massachusetts, USA

    • Kelly C Cushing
    • , John Garber
    •  & Hamed Khalili
  2. Department of Pathology, Massachusetts General Hospital, Boston, Massachusetts, USA

    • Mari Mino-Kenudson
  3. Clinical and Translational Epidemiology Unit, Massachusetts General Hospital, Boston, Massachusetts, USA

    • Paul Lochhead

Authors

  1. Search for Kelly C Cushing in:

  2. Search for Mari Mino-Kenudson in:

  3. Search for John Garber in:

  4. Search for Paul Lochhead in:

  5. Search for Hamed Khalili in:

Competing interests

Guarantor of the article: Hamed Khalili, MD, MPH.

Specific author contributions: Kelly C. Cushing: drafting the manuscript; revisions of the manuscript; approval of the final draft submitted. Mari Mino-Kenudson: preparation of Images; revisions of the manuscript; approval of the final draft submitted. John Garber: approval of the final draft submitted. Paul Lochhead: revisions of the manuscript; approval of the final draft submitted. Hamed Khalili: revisions of the manuscript; approval of the final draft submitted.

Financial support: None.

Potential competing interests: John Garber receives grant funding for investigator-initiated sponsored research (IISR) through Takeda Pharmaceuticals. Hamed Khalili has received research funding from Takeda and has served as a consultant for Abbvie and Samsung Bioepis.

Corresponding author

Correspondence to Kelly C Cushing.

About this article

Publication history

Published

DOI

https://doi.org/10.1038/ajg.2018.7